

NCATS Inxight FRDB: Fast Response DataBase for Drug Repositioning

Oleg Stroganov¹, Ivan Grishagin^{1,2}, Joseph Ramirez¹, Tania Khasanova¹, Noel Southall^{2,3}, Ewy Mathé², Julie Bryant¹

¹ Rancho BioSciences, LLC, 16955 Via Del Campo #220, San Diego, CA 92127

² National Center for Advancing Translational Sciences (NCATS), 6701 Democracy Boulevard, Bethesda, MD

³ AstraZeneca, 1 Medimmune Way, Gaithersburg, MD 20878

Email: Oleg.Stroganov@RanchoBioSciences.com

Background and Goal

During healthcare emergencies, it is **critical to discover treatments very quickly**. The only solution to this is the repositioning and repurposing of existing approved and investigational drugs.

To test a drug candidate in the clinic, one should have answers to these questions:

- Is the compound active against its presumed target?
- Is it possible to achieve the required concentration in patients?
- How toxic is the compound? Can it be used in combination with other drugs?
- How to source the compound?

Here, we describe Fast Response DataBase (FRDB), a web resource designed to answer those questions. FRDB leverages an existing **NCATS¹ Inxight Drugs** web portal² and adds manually curated data about drug **pharmacokinetics**, **adverse events**, **drug-drug interactions**, and **sourcing** to aid drug repositioning and PK/PD modeling.

¹ This research was supported in part by the Intramural/Extramural research program of the NCATS, NIH.

² Sramshetty VB, Grishagin I, Nguyen DT, et al. NCATS Inxight Drugs: a comprehensive and curated portal for translational research. Nucleic Acids Res. 2022;50(D1):D1307-D1316. doi:10.1093/nar/gkab918

FRDB Core Data

Pharmacokinetics (PK)

- **Key metrics:** C_{max} , AUC, $t_{1/2}$, $F_{unbound}$ for parent drug and active metabolite
- **Administration:** route, dose, and frequency
- **Population metadata:** health status, food status, sex
- **Reference:** FDA labels, review documents, articles, reviews, ClinicalTrials.gov, etc.

Adverse Events (AEs) / Toxicity (Tox)

- **Highest dose** tested in clinical trials for each administration route and regimen
- AEs leading to drug **discontinuation**, **dose reduction** or **interruption**
- Dose-limiting toxicities (**DLTs**) and maximum tolerated doses (**MTDs**)
- **Overdosage reports** with corresponding AEs and AEs resulting in FDA black box warnings
- **AEs for recommended dose** (for limited subset of drugs)
- **Administration:** route, dose, and frequency

Drug-Drug Interactions (DDIs)

- **Relationships** between **drugs** and their **metabolites**, **DDI** and **Tox** targets
- *In vitro* **IC₅₀**, **inhibition %** at specific concentrations, **Ki**
- **Clinical relevance:** strength of interactions, type of experiment, exposure change

Inxight Drugs




- 👍 Approval status
- 🎯 Targets
- 🏥 Indications
- ⋮ Properties

FRDB Stats

Records
23,500 Total
1,400 Have clinical evidence

Records
15,500 Total




Records
53,600 Total
2,560 DLT
10,400 Leading to discontinuation or dose reduction

Sourcing Records
66,600


2,726 Total Drugs

- US approved
- Previously approved
- Investigational

FRDB use case: PK prediction



FRDB use case: anti-targets



FRDB data are publicly available at <https://drugs.ncats.io>. Complete dataset is available for direct download as well at <https://drugs.ncats.io/downloads-public>

This work was supported in part by the intramural/extramural research program of NCATS, NIH (ZIC TR000410-03, ZIA TR000344).